CN1189159C - 含水溶性美容活性组分水性核的微胶囊及含其的组合物 - Google Patents
含水溶性美容活性组分水性核的微胶囊及含其的组合物 Download PDFInfo
- Publication number
- CN1189159C CN1189159C CNB011156287A CN01115628A CN1189159C CN 1189159 C CN1189159 C CN 1189159C CN B011156287 A CNB011156287 A CN B011156287A CN 01115628 A CN01115628 A CN 01115628A CN 1189159 C CN1189159 C CN 1189159C
- Authority
- CN
- China
- Prior art keywords
- microcapsule
- water
- wax
- polymer
- cellulose esters
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003094 microcapsule Substances 0.000 title claims abstract description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 44
- 239000000203 mixture Substances 0.000 title claims description 24
- 230000000694 effects Effects 0.000 title claims description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 33
- 239000001993 wax Substances 0.000 claims abstract description 28
- 229920002678 cellulose Polymers 0.000 claims abstract description 16
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims abstract description 7
- 229920001610 polycaprolactone Polymers 0.000 claims abstract description 6
- 239000004632 polycaprolactone Substances 0.000 claims abstract description 6
- 239000012188 paraffin wax Substances 0.000 claims abstract description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 239000000839 emulsion Substances 0.000 claims description 21
- 235000010323 ascorbic acid Nutrition 0.000 claims description 19
- 229960005070 ascorbic acid Drugs 0.000 claims description 19
- 239000011668 ascorbic acid Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 230000003796 beauty Effects 0.000 claims description 18
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- 230000003213 activating effect Effects 0.000 claims description 15
- 239000008346 aqueous phase Substances 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- 239000007766 cera flava Substances 0.000 claims description 8
- 102000018832 Cytochromes Human genes 0.000 claims description 7
- 108010052832 Cytochromes Proteins 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 239000002002 slurry Substances 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 150000001735 carboxylic acids Chemical class 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 150000005846 sugar alcohols Polymers 0.000 claims description 4
- 235000012756 tartrazine Nutrition 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- -1 poly(3-hydroxybutyrate) Polymers 0.000 abstract description 20
- 239000002537 cosmetic Substances 0.000 abstract description 13
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 abstract description 12
- 229920001577 copolymer Polymers 0.000 abstract description 7
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 abstract description 6
- 229920001897 terpolymer Polymers 0.000 abstract description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract description 3
- 239000005977 Ethylene Substances 0.000 abstract description 3
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 abstract description 3
- BXOUVIIITJXIKB-UHFFFAOYSA-N ethene;styrene Chemical group C=C.C=CC1=CC=CC=C1 BXOUVIIITJXIKB-UHFFFAOYSA-N 0.000 abstract description 3
- 229920000921 polyethylene adipate Polymers 0.000 abstract description 3
- 229920005996 polystyrene-poly(ethylene-butylene)-polystyrene Polymers 0.000 abstract description 3
- 235000013871 bee wax Nutrition 0.000 abstract 2
- 239000012166 beeswax Substances 0.000 abstract 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 239000010773 plant oil Substances 0.000 abstract 1
- 229920000070 poly-3-hydroxybutyrate Polymers 0.000 abstract 1
- 229920001296 polysiloxane Polymers 0.000 abstract 1
- 238000007789 sealing Methods 0.000 description 17
- 239000000725 suspension Substances 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 241001597008 Nomeidae Species 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- 239000013543 active substance Substances 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000000935 solvent evaporation Methods 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 238000012695 Interfacial polymerization Methods 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000001361 adipic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000004531 microgranule Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 229940117958 vinyl acetate Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JIMKNCCELIMQPR-UHFFFAOYSA-N (7,7-dimethyl-2-methylidene-3-oxo-4-bicyclo[2.2.1]heptanyl)methanesulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)C(=C)C1C2(C)C JIMKNCCELIMQPR-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 206010047631 Vitamin E deficiency Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-BFWOXRRGSA-N [(2r)-2-[(3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)C1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-BFWOXRRGSA-N 0.000 description 1
- MNKNLPPKUOUFGP-UHFFFAOYSA-N [O].CCCCCCCCCCCCCCCCCCCCCC Chemical compound [O].CCCCCCCCCCCCCCCCCCCCCC MNKNLPPKUOUFGP-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 239000000823 artificial membrane Substances 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- QDYLMAYUEZBUFO-UHFFFAOYSA-N cetalkonium chloride Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 QDYLMAYUEZBUFO-UHFFFAOYSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- UVCJGUGAGLDPAA-UHFFFAOYSA-N ensulizole Chemical compound N1C2=CC(S(=O)(=O)O)=CC=C2N=C1C1=CC=CC=C1 UVCJGUGAGLDPAA-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- LWIGVRDDANOFTD-UHFFFAOYSA-N hydroxy(dimethyl)silane Chemical compound C[SiH](C)O LWIGVRDDANOFTD-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229950007687 macrogol ester Drugs 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 238000005554 pickling Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229940081510 piroctone olamine Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000011252 protective cream Substances 0.000 description 1
- 239000011250 protective ointment Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 description 1
- 229960002026 pyrithione Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/58—Metal complex; Coordination compounds
Abstract
本发明涉及微胶囊,具有含至少一种水溶性美容或护肤活性组分的水性核,和聚合物和/或蜡包膜,所述包膜组成为:至少一种选自聚己酸内酯、聚(3-羟基丁酸酯)、聚己二酸亚乙基酯、聚己二酸亚丁基酯、至少一种C1~C4羧酸的纤维素酯、苯乙烯和马来酸酐的共聚物、苯乙烯和丙烯酸的共聚物、苯乙烯-乙烯/丁烯-苯乙烯三元嵌段共聚物、苯乙烯-乙烯/丙烯-苯乙烯三元嵌段共聚物、及乙烯,醋酸乙烯酯和马来酸酐的三元共聚物的聚合物,和/或至少一种选自蜂蜡、多甘油化蜂蜡、氢化植物油、熔点在45℃以上的石蜡,和硅氧烷蜡的腊。
Description
技术领域
本发明涉及具有含至少一种水溶性美容或护肤活性组分的水性核的微胶囊,含该微胶囊的美容或护肤组合物以及该微胶囊的制备方法。
背景技术
众所周知,将化妆品或护肤品中的活性剂进行微胶囊包封,能使其更好地贮存和/或持续地并控制地释放。
微胶囊包封的方法及其原理在例如《微胶囊包封,方法和工业应用》,Benita,M.Dekkr主编,1996年一书中有详细的描述。
在所有微胶囊包封方法中,均使用聚合物作为将活性试剂与外界媒介隔离的微粒壁的组成成分。这些微粒可以比其他的微孔体系,例如脂质体,即采用双层磷脂膜包围水性核所形成的微粒,更好地包封水溶性的活性试剂。
人们一直试图包封各种亲水性活性试剂。其中,最感兴趣的是抗坏血酸,尽管它具有许多有益的性能,但由于其在水性介质中的不稳定性,使其难以复配在化妆品组合物中。
特别地,由于其化学结构(α-酮内酯)的原因,抗坏血酸对于某些环境因素,例如光、氧或水等十分敏感。这导致在这些试剂的存在下,复配在化妆品中的抗坏血酸会迅速降解。这种不稳定性会减弱它的功效,尽管抗坏血酸是一种非常好的活性剂,可以用于刺激结缔体素,特别是胶原质的合成,增强皮肤组织抵抗外界侵蚀,例如紫外线辐射和空气污染的能力,补偿皮肤的维生素E缺乏,使皮肤增白,和捕捉自由基等。特别地,这些性能使得抗坏血酸是一种优异的化妆品或护肤品活性剂,用于抵抗或防止皮肤老化。
在以溶解,分散或研磨的形式包封象抗坏血酸这类亲水性活性组分的技术中,应该提到凝聚(JP-8 325 117,JP-5 285 210和US 4 460563),喷雾干燥(US 5 767 107),空气床流化法(WO 95/27488和EP0 600 775),或界面聚合法(JP 1 043 343,WO 91/01801和WO 9423832)。
喷雾干燥法和空气床流化法的主要缺点是,活性剂是以粉末形式,即固体形式包封的。而现在的化妆品或护肤品中,经常需要以溶解的形式将活性剂包封在水性介质中,以保证其对于皮肤的直接的生物药效率。
凝聚技术或界面聚合技术也不适于这种水溶性美容或护肤活性成分的微胶囊包封,因为这些技术中通常使用了可聚合的或双官能团的反应物,它们对皮肤有毒,而且容易与被包封的活性剂反应,从而使其失活。
另一种微胶囊化方法也可以用来将溶解的亲水性活性剂包封在微颗粒中,这就是《多级乳化-溶剂蒸发或萃取》技术,它包括以下步骤:通过将活性组分的水溶液分散在不溶水的聚合物的有机溶液中,制备油包水的初级乳液,然后在第二阶段,将此初级乳液分散于外水相中。然后通过蒸发或萃取方法脱除有机溶剂。
这一方法公开在专利US-3 523 906,US-3 523 907,EP 190 833,和WO 95/28149中。
US-3 523 906和US-3 523 907分别公开了多级乳化-蒸发方法和多级乳化-萃取方法,其采用以下聚合物作为微胶囊的包膜材料:乙烯基均聚物或共聚物,缩聚物如聚碳酸酯、聚酯、聚磺酸酯、聚氨酯或聚酰胺,或天然聚合物如氯化天然橡胶或纤维素衍生物。
专利申请EP 190 833公开了一种水溶性活性成分的包封方法,采用多级乳化-溶剂蒸发的方法,使用了不溶于水的生物相容的聚合物,特别是基于乳酸和羟基乙酸的聚合物。
专利申请WO 95/28149公开了通过多级乳化-蒸发技术制备微胶囊的方法,该微胶囊壁由聚(丙交酯-乙交酯)型共聚物构成。
本申请人现已发现,上述专利文献中所公开的聚合物并不适于稳定活性组分,这或者是因为它们在水性介质中会水解释放出有机酸,从而会改变所述组合物的pH值,或者是因为它们无法达到令人满意的包封度。
本发明提供了一种新的微胶囊,解决了上述问题,其包膜中含有在水性介质中稳定的聚合物,并且对于水溶性活性组分的包封度令人满意。
美容活性组分包封的另一个特殊问题,与美容组合物中存在的水有关。
具体而言,微胶囊外水相的存在,要求这些微胶囊壁具有优异的不可渗透性,以防止活性组分渗入到外部水相中,那样将削弱包封所带来的所有优点。因此,在化妆品领域,非常需要一种具有非渗透壁的微胶囊,其仅仅在使用后,在例如包层材料破裂或生物降解后才释放出活性成分。
在医药领域不存在上述问题,因为在此领域微胶囊一般是以干燥的形式存在,并要求其在与水性介质接触后快速释放出活性成分。
本申请人发现,解决上述现有技术中存在的问题是可能的,即通过从某些聚合物和/或某些蜡中适当地选择材料以形成包封材料,得到具有满意包封度的包括包封膜的微胶囊,该微胶囊含有至少一种被稳定化的美容或护肤活性成分的水溶液。
发明内容
本发明的一个目的是提供微胶囊,其具有含至少一种水溶性美容或护肤活性组分的水性核,和聚合物和/或蜡包膜,所述的包膜由以下组分组成:
选自以下聚合物中的至少一种:聚己酸内酯、聚(3-羟基丁酸酯)、聚己二酸亚乙基酯、聚己二酸亚丁基酯、至少一种C1~C4羧酸的纤维素酯,优选两种羧酸的混合纤维素酯、苯乙烯和马来酸酐的共聚物、苯乙烯和丙烯酸的共聚物、苯乙烯-乙烯/丁烯-苯乙烯三元嵌段共聚物、苯乙烯-乙烯/丙烯-苯乙烯三元嵌段共聚物、及乙烯,醋酸乙烯酯和马来酸酐的三元共聚物,和/或
选自以下蜡中的至少一种:蜂蜡、多甘油化蜂蜡、氢化植物油、熔点在45℃以上的石蜡,和硅氧烷蜡。
为实现本发明目的,采用的蜡是一种亲脂性化合物,其在室温下(约25℃)是固体,可进行可逆的固液相变,其熔点在约40℃以上,可以高达200℃,并且其在固态时具有各向异性的晶体结构。
可以采用硅氧烷蜡,例如,含有16~45个碳原子的烷基和烷氧基二甲基硅氧烷,例如二十二碳烷氧基二甲基硅氧烷,和C16~C45二甲基硅氧烷醇的烷基酯,例如二甲基硅醇的二十二碳烷酸酯。
本发明的另一个目的是提供美容或护肤组合物,该组合物含有前述具有水性核和聚合物和/或蜡包封膜的微胶囊,所述微胶囊负载在生理学可接受的载体上。
本发明的又一个目的是提供一种通过多级乳化-溶剂蒸发工艺,制备上述具有水性核和聚合物和/或蜡包封膜的微胶囊的方法。
本发明的微胶囊对水溶性活性组分可以得到满意的包封度,其相对于所使用的活性剂的重量,至少可以达到70%,或甚至达到95%以上。
这些微胶囊的优点在于,限制了被包封的亲水性活性成分的损失。
在本发明的一个实施方案中,由一种或多种前述聚合物与至少一种选自前述蜡化合物的蜡形成包封膜。
在制备初级乳液前,这些蜡与本发明所使用的有机可溶的聚合物一起溶解在有机溶剂中。
被包封的活性剂,可以是任何具有美容或护肤活性的水溶性分子。可以提到的实例是:
—自由基清扫剂和/或解毒剂,如抗坏血酸及其衍生物,例如:抗坏血酰磷酸镁,半胱氨酸衍生物,如N-乙酰基半胱氨酸,蛋白质,肽及其衍生物,辅酶Q和细胞色素C,
—角质层分离剂,如α-羟基酸,β-羟基酸和α-酮酸,例如水杨酸及其衍生物,
—加速晒黑剂,例如酪氨酸的衍生物,
—脱色活性剂,例如曲酸和对苯二酚葡糖苷和它们的衍生物,
—紫外线屏蔽剂,例如含有磺酸官能团的屏蔽剂,特别是2-苯基苯并咪唑-5-磺酸,sulisobenzone,和苯-1,4-双(3-亚甲基-10-樟脑磺酸),
—自晒黑活性剂,例如二羟基丙酮和吲哚,
—脂调节剂,例如咖啡因和茶碱,
—增湿剂,例如山梨糖醇,木糖醇,脲和植物DNA,
—去头皮屑剂,例如piroctone olamine和吡啶硫酮衍生物,
—光亮剂,例如1,2-二苯乙烯衍生物,和着色剂,例如酒石黄的钠盐,
—从植物中提取的天然着色剂,例如叶绿酸(chlorophylline),或从动物中提取的天然着色剂,例如胭脂虫红,或焦糖,
及这些活性组分的混合物。
本发明的微胶囊,特别适合于包封对周围的各种物理化学因素,例如温度、pH值、氧气、氧化剂或重金属的存在、光或紫外线辐射敏感的不稳定的活性成分。具体而言,胶囊化可以产生一个稳定的小环境,使活性成分与化妆品组合物中含有的或作用于组合物上的物化试剂隔离开来。
所述的不稳定的水溶性美容或护肤活性组分,可以作为实例而特别提到的是抗坏血酸及其盐,特别是其钠盐、钾盐、镁盐或钙盐。
为了获得美容或护肤的效果,在被包封的内部水相中,活性组分的浓度一般为被包封的内部水相总重量的0.1%~50%,优选为5%~25%,还可以为0.1~5%重量。人们可能需要包封相当高浓度的溶液,这样活性组分的浓度上限取决于该活性剂在被包封的内部水相中的溶解度。
微胶囊的水性核,即活性组分溶解于其中的油包水型初级乳液的被包封的内部水相,还可以以溶解的形式,含有一种或多种水溶性的聚合物,和/或一种或多种低分子量的多元醇。水溶性聚合物的作用是稳定初级乳液,和/或防止微胶囊中被包封的活性组分流失。多元醇的作用是通过降低被包封的内部水相中水的活性来稳定活性剂。
所述的水溶性聚合物特别选自聚乙烯醇、聚乙烯基吡咯烷酮、羧甲基纤维素、聚羧酸以及它们的交联衍生物,和天然树胶,例如黄原胶、淀粉、藻酸钠盐、果胶、脱乙酰壳多糖、瓜耳胶、角豆树胶和角叉(菜)胶。这些水溶性聚合物的加入量,相对于被包封的内部水相的总重量,为0.01%~10%(重量),优选为0.1%~5%(重量)。
低分子量多元醇是选自,例如,甘油和C2~C5亚烷基二醇,特别是丙二醇和戊二醇,其存在量相对于被包封的内部水相的总重量,可为10%~90%(重量),优选量为10%~50%(重量)。
初级乳液的被包封的内部水相中,还可以含有稳定该初级乳液的盐。该盐选自例如氯化钠,氯化钾,硫酸镁,和氯化镁,其加入量相对于被包封的内部水相的总重量,通常为0.1%~5%(重量),优选为0.1%~1%(重量)。
最后,初级乳液的被包封的内部水相中,还可以含有抗氧剂。
微胶囊的大小和内部结构依制备方法相关的许多参数而定,例如温度,乳化过程中的搅拌速度,各种水溶性的和有机可溶的组份的化学结构和各自的加入量,稳定剂的加入量,等等。本领域的技术人员知道如何调整这些不同的参数,以获得所需要的微胶囊形态。
特别地,所述微胶囊可以是单液泡的或多液泡的,即外层包膜可以仅包含一个水相区域,或者作为选择之一,内部的水相被与外层包膜具有相同化学结构的壁分格成多个区域。这种现象通常在多级乳液特别稳定时发生,而且具有优异的包封效果。
形成本发明微胶囊核心的被包封的内部水相与微胶囊包层(聚合物和/或蜡)之间的重量比通常为0.1/1~50/1,优选为0.5/1~10/1。
本发明微胶囊的平均直径一般为1μm~1000μm,更优选为1μm~50μm,最优选为1μm~25μm。
本发明的一个目的是提供美容或护肤组合物,该组合物包括负载在一种生理学可接受的载体上的前述具有水性核和聚合物和/或蜡包膜的微胶囊。
特别地,在化妆品组合物中,聚合物和/或蜡的浓度为0.5%~10%(重量),优选为1%~5%(重量)。
含有本发明微胶囊的美容或护肤组合物中,还可以含有化妆品或护肤品中常用的辅剂,例如脂肪质、凡士林、pH值调节剂、香味剂、防腐剂、增稠剂或胶凝剂、着色剂、防沫剂或螯合剂。
显而易见的是,本领域技术人员应谨慎选择这些任选的添加化合物及其用量,以使本发明的美容或护肤组合物所特有的优良性能不会,或基本上不会受到添加物的副影响。
本发明的美容或护肤组合物可以采用例如以下形式:浆液、洗液、水溶液、水-醇或油凝胶、油包水或水包油的乳液、或无水的形态。
这些组合物特别适合于制造脸、手或身体的防护膏、药膏或护理膏,对身体进行防护或护理的奶液,对皮肤进行护理或治疗的洗液、凝胶或摩丝,清洗液,粉底和着色膏,唇膏或睫毛膏。在后述的应用中,本发明的组合物还可以含有色素。
本发明的一个目的是提供一种制备上述的具有含水溶性美容或护肤活性组分的水性核,及聚合物和/或蜡包膜的微胶囊的方法。该方法通过多级乳化-溶剂蒸发,实现微胶囊化,包含下列连续步骤:
(a)在水相中溶解至少一种美容或护肤活性剂,
(b)在至少一种聚合物和/或至少一种蜡与一种与水不混溶的有机溶剂形成的溶液中,将步骤(a)得到的水溶液乳化,所述聚合物选自:聚己酸内酯、聚(3-羟基丁酸酯)、聚己二酸亚乙基酯、至少一种C1~C4羧酸的纤维素酯,优选两种羧酸的混合纤维素酯、聚己二酸亚丁基酯、苯乙烯和马来酸酐的共聚物、苯乙烯和丙烯酸的共聚物、苯乙烯-乙烯/丁烯-苯乙烯三元嵌段共聚物、苯乙烯-乙烯/丙烯-苯乙烯三元嵌段共聚物、及乙烯,醋酸乙烯酯和马来酸酐的三元共聚物,所述蜡选自:蜂蜡、多甘油化蜂蜡、氢化植物油、熔点在45℃以上的石蜡,和硅氧烷蜡,
(c)在优选含有乳液稳定剂的水溶液中,乳化步骤(b)得到的油包水型初级乳液,
(d)蒸发脱除有机溶剂,得到微胶囊的水悬浮液。
步骤(b)所使用的与水不混溶的有机溶剂,通常根据其对于包膜材料的溶解能力,其在水中的溶解度,及其沸点进行选择,其在水中的溶解度应尽可能的低,其沸点优选低于100℃。可以使用例如二氯甲烷、环己烷、庚烷、1-氯丁烷和乙酸乙酯。
多级乳液的稳定性是能否获得好的包封效果的决定因素。具体而言,稳定性差的多级乳液将导致包膜内外水相的混合,使活性成分从已形成的乳粒中流失。因此强烈推荐在步骤(c)得到的连续水相中加入乳液稳定剂。
适宜的聚合物稳定剂是本领域已知的,可选自例如:聚乙烯醇、聚乙烯基吡咯烷酮、苯乙烯-马来酸酐水溶性共聚物、羧甲基纤维素、淀粉、脱乙酰壳多糖、和聚丙烯酸。
尽管优选使用聚合物稳定剂,但也可以使用水溶性的表面活性剂来代替。
为了增加多级乳液的稳定性,乳液的连续相中还可以含有0.1%~10%(重量)的矿物盐,所述矿物盐选自例如:氯化钠、氯化钾、硫酸镁和氯化镁。
为了改善初级乳液的稳定性,还可以向步骤(b)的有机溶剂形成溶液中加入表面活性剂。本领域的技术人员知道如何选择适当的化合物,例如:HLB(亲水亲油平衡)小于10的表面活性剂,如脂肪酸山梨醇酯类,多乙氧基醚,脂溶的卵磷脂,脂肪酸单甘油酯,聚乙二醇-30二聚氢化硬脂酸酯(ICI公司的ArlacelP135),十六烷基二甲基硅烷-多元醇(Goldschmidt公司的AbilEM90),和氧乙烯化聚二甲基硅氧烷(Dow化学公司的DC2-5695)。
将溶剂蒸发后所得到的微胶囊悬浮液,可直接使用,也可以配制成美容或护肤组合物使用。
如果需要,也可以通过过滤,从步骤(d)得到的水悬浮液中分离出微胶囊,然后可进行干燥,得到微胶囊粉末。
下面给出了包封两种对热敏感的美容活性剂的实例。
具体实施方式
实施例1
细胞色素C微胶囊
将细胞色素C(可从Sigma公司购得,商品号C3256)配制成0.25%(重量)的水溶液。使用一个转子-定子型均化器,将5ml上述溶液加入到50ml含5%乙酰丁酸纤维素(CAB-381-05,EastmanChemical)的二氯甲烷中乳化5分钟,同时保持温度低于25℃。然后,在Moritz分散器中,在室温下,将该初始乳液在500ml含1%聚乙烯醇(Rhodoviol 4-125,Rhodia Chimie)的水溶液中分散20分钟。
采用旋转蒸发仪(Buchi B-480),将上述悬浮液在40℃,75kPa压力下蒸发5小时,除去溶剂。
这样得到了平均直径为22微米的微胶囊水悬浮液。
在紫外-可见光分光光度计上,波长为506纳米处,可检测细胞色素C。
包封度,即微胶囊中活性剂的浓度与活性剂的总浓度之比为97%。制造收率,即在生产结束时回收的活性剂量与最初加入的活性剂量之比为100%。
将所得到的微胶囊悬浮液在45℃贮存2个月。贮存结束后,测量细胞色素C从悬浮液中损失的量,并测量在相同条件下贮存的浓度同样为0.25%(重量)的细胞色素C对照水溶液的损失量。得到的结果列于下表。
实施例2
叶绿酸微胶囊
将叶绿酸配制成0.1%(重量)的水溶液。使用一个转子-定子型均化器,将5ml该溶液加入到50ml含5%聚(己酸内酯)(CAPA640,Solvay)的二氯甲烷中乳化5分钟,同时保持温度低于25℃。然后,在Moritz分散器中,在室温下,将该初始乳液在500ml含1%聚乙烯醇(Rhodoviol 4-125,Rhodia Chimie)的水溶液中分散20分钟。
采用旋转蒸发仪(Buchi B-480),将上述悬浮液在40℃,75kPa压力下蒸发5小时,除去溶剂。
这样得到了平均直径为15微米的微胶囊水悬浮液。
在紫外-可见光分光光度计上,波长为405纳米处,可检测叶绿酸。
包封度为90%,制造收率为100%。
将所得到的微胶囊悬浮液在45℃贮存2个月。贮存结束后,测量叶绿酸从悬浮液中损失的量,并测量在相同条件下贮存的浓度同样为0.1%(重量)的叶绿酸对照水溶液的损失量。得到的结果列于下表。
实施例3
抗坏血酸微胶囊
将抗坏血酸配制成浓度为5%(重量),PH值为6的水溶液。使用一个转子-定子型均化器,将5ml该溶液加入到50ml含5%乙酰丙酸纤维素酯(CAP-482-0.5,Eastman Chemical)的二氯甲烷中乳化5分钟,同时保持温度低于25℃。然后,在Moritz分散器中,在室温下,将该初始乳液在500ml含1%聚乙烯醇(Airvol 203,Air Products)和7%氯化钠的水溶液中分散20分钟。
采用旋转蒸发仪(Buchi B-480),将上述悬浮液在40℃,75kPa压力下蒸发5小时,除去溶剂。
得到的微胶囊的平均大小为20微米。
采用HPLC,在浓度为0.1mol/l,pH值为2.1的磷酸盐缓冲溶液中,在257纳米的检测波长,检测抗坏血酸。
包封度为85%,制造收率为100%。
将所得到的微胶囊悬浮液在45℃贮存2个月。贮存结束后,测量抗坏血酸从悬浮液中损失的量,并测量在相同条件下贮存的浓度同样为5%(重量),pH值同样为6的抗坏血酸对照水溶液的损失量。得到的结果列于下表。
实施例4(比较例)
将抗坏血酸配制成浓度为10%(重量),PH值为6的水溶液。使用一个转子-定子型均化器,将5ml该溶液加入到50ml含5%聚苯乙烯(PM50000,Polysciences)的二氯甲烷中乳化5分钟,同时保持温度低于25℃。然后,在Moritz分散器中,在室温下,将该初始乳液在500ml含1%聚乙烯醇(Airvol 203,Air Products)和7%氯化钠的水溶液中分散20分钟。
采用旋转蒸发仪(Buchi B-480),将上述悬浮液在40℃,75kPa压力下蒸发5小时,除去溶剂。
得到的颗粒的平均大小为15微米。
采用HPLC,在浓度为0.1mol/l,pH值为2.1的磷酸盐缓冲溶液中,在257纳米的检测波长,检测抗坏血酸。
包封度为0%,制造收率为100%。
实施例5(比较例)
将抗坏血酸配制成浓度为10%(重量),PH值为6的水溶液。使用一个转子-定子型均化器,将5ml该溶液加入到50ml含5%乙基纤维素(EthocelStandard FP Premium,Dow Chemical)的二氯甲烷中乳化5分钟,同时保持温度低于25℃。然后,在Moritz分散器中,在室温下,将该初始乳液在500ml含1%聚乙烯醇(Airvol 203,Air Products)和7.5%氯化钠的水溶液中分散20分钟。
采用旋转蒸发仪(Buchi B-480),将上述悬浮液在40℃,75kPa压力下蒸发5小时,除去溶剂。
得到的微胶囊的平均大小为18微米。
采用HPLC,在浓度为0.1mol/l,pH值为2.1的磷酸盐缓冲溶液中,在257纳米的检测波长,检测抗坏血酸。
包封度为17%,制造收率为100%。
表
包封度 | 在45℃贮存2个月后活性剂的损失 | ||
包封的活性剂 | 未包封的对照样 | ||
实施例1 | 97% | 0% | 60% |
实施例2 | 90% | 10% | 60% |
实施例3 | 85% | 20% | 40% |
实施例4(比较) | 0% | - | - |
实施例5(比较) | 17% | - | - |
这些对比试验表明,使用纤维素酯(实施例1和3)或聚己酸内酯(实施例2)代替聚苯乙烯(比较例4)或纤维素醚(比较例5),可获得较高的包封度。而且可以发现,本发明的微胶囊可以使其中包封的美容活性剂具有更好的化学稳定性。
实施例6
酒石黄微胶囊
将酒石黄配制成0.1%(重量)的水溶液。使用一个转子-定子型均化器,将5ml该溶液加入到50ml含5%乙酰丙酸纤维素酯(CAP-482-0.5,Eastman Chemical)与蜂蜡的90/10混合物的二氯甲烷中,乳化5分钟,同时保持温度低于25℃。然后,在Moritz分散器中,在室温下,将该初始乳液在500ml含1%聚乙烯醇(Airvol 203,Air Products)的水溶液中分散20分钟。
采用旋转蒸发仪(Buchi B-480),将上述悬浮液在40℃,75kPa压力下蒸发5小时,除去溶剂。
得到的微胶囊的平均大小为25微米。
包封度为98%,制造收率为100%。
实施例7
含有实施例3的微胶囊的日霜
A相
十六烷醇 4g
山梨醇三硬脂酸酯 0.9g
硬脂酸聚乙二醇酯 2g
硬脂酸甘油酯 3g
十四烷酸十四烷酯 2g
棕榈酸辛酯 4.5g
Parsol MCX(Hoffman-Laroche出售) 3g
环戊基硅氧烷 5g
防腐剂 0.1g
B相
软化水 60.3g
防腐剂 0.15g
螯合剂 0.05g
C相
实施例3的微胶囊粉末 15g
将A相和B相快速加热至75℃,并使用Moritz搅拌器(Turbolab2100)将其混合在一起。然后在持续的搅拌下将该乳液降至室温,然后在Heidolph(RZR 2040)桨式搅拌器轻轻搅拌下,将微胶囊粉末(C相)缓慢地加入到其中。
Claims (14)
1.微胶囊,具有水性核和包膜,所述水性核含至少一种选自抗坏血酸或其衍生物、细胞色素C、叶绿酸、酒石黄或其盐的水溶性美容或护肤活性组分,所述包膜由聚合物和任选的蜡组成,其特征在于:
所述聚合物为选自以下聚合物中的至少一种:聚己酸内酯、至少一种C1~C4羧酸的纤维素酯,和
所述蜡为选自以下蜡中的至少一种:蜂蜡、多甘油化蜂蜡、氢化植物油、熔点在45℃以上的石蜡,和硅氧烷蜡。
2.根据权利要求1的微胶囊,其特征在于,其中所述的至少一种C1~C4羧酸的纤维素酯是两种羧酸的混和纤维素酯。
3.根据权利要求1的微胶囊,其特征在于,所述的包膜由至少一种所述的聚合物和至少一种所述的蜡组成。
4.根据权利要求1的微胶囊,其特征在于,所述的活性成分是抗坏血酸或其盐。
5.根据前述任一权利要求的微胶囊,其特征在于,在被包封的内部水相中,相对于被包封的内部水相总重量,所述活性成分的浓度为0.1~5%重量。
6.根据权利要求1的微胶囊,其特征在于,所述水性核还含有选自甘油和C2-C5亚烷基二醇的低分子量的多元醇。
7.根据权利要求1的微胶囊,其特征在于,所述水性核还含有聚乙烯醇。
8.根据权利要求1的微胶囊,其特征在于,所述微胶囊的平均直径为1μm~25μm。
9.美容用或护肤用组合物,含有权利要求1~8中任意一项的具有水性核和包膜的微胶囊,所述微胶囊负载在生理学可接受的载体上。
10.权利要求1~8中任意一项的微胶囊的制备方法,包括下列连续步骤:
(a)将至少一种美容用或护肤用活性剂溶解在水相中,
(b)在至少一种聚合物和任选的至少一种蜡,与一种与水不混溶的有机溶剂形成的溶液中,将步骤(a)得到的水溶液乳化,
(c)在水溶液中,将步骤(b)得到的油包水初级乳液乳化,
(d)蒸发脱除有机溶剂,得到微胶囊的水悬浮液,其特征在于,步骤(b)中所使用的聚合物选自下列聚合物组:聚己酸内酯、至少一种C1~C4羧酸的纤维素酯,并且所述的蜡选自蜂蜡、多甘油化蜂蜡、氢化植物油、熔点在45℃以上的石蜡,和硅氧烷蜡。
11.根据权利要求10的方法,其特征在于,步骤(d)中所述的至少一种C1~C4羧酸的纤维素酯是两种羧酸的混和纤维素酯。
12.根据权利要求10的方法,其特征在于,步骤(b)中所使用的与水不混溶的有机溶剂选自二氯甲烷。
13.根据权利要求10的方法,其特征在于,步骤(c)中所述的水溶液含有乳液稳定剂。
14.根据权利要求13的方法,其特征在于,所述的乳液稳定剂选自聚乙烯醇。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0005756 | 2000-05-05 | ||
FRFR0005756 | 2000-05-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1323579A CN1323579A (zh) | 2001-11-28 |
CN1189159C true CN1189159C (zh) | 2005-02-16 |
Family
ID=8849925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB011156287A Expired - Fee Related CN1189159C (zh) | 2000-05-05 | 2001-04-28 | 含水溶性美容活性组分水性核的微胶囊及含其的组合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6531160B2 (zh) |
EP (1) | EP1151741B1 (zh) |
JP (1) | JP3933886B2 (zh) |
CN (1) | CN1189159C (zh) |
AT (1) | ATE343365T1 (zh) |
CA (1) | CA2346320C (zh) |
DE (1) | DE60124028T2 (zh) |
ES (1) | ES2269322T3 (zh) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2792122C (en) * | 1997-07-07 | 2015-09-08 | Medical Research Council | In vitro sorting method |
GB9900298D0 (en) * | 1999-01-07 | 1999-02-24 | Medical Res Council | Optical sorting method |
US6685927B2 (en) * | 2001-09-27 | 2004-02-03 | Ceramoptec Industries, Inc. | Topical application of chromophores for hair removal |
GB0127564D0 (en) * | 2001-11-16 | 2002-01-09 | Medical Res Council | Emulsion compositions |
FR2832630B1 (fr) * | 2001-11-28 | 2005-01-14 | Oreal | Composition cosmetique et/ou dermatologique contenant au moins un actif hydrophile sensible a l'oxydation stabilise par au moins un copolymere de n-vinylimidazole |
ES2254885T3 (es) * | 2002-06-20 | 2006-06-16 | L'oreal | Utilizacion cosmetica y/o dermatologica de una composicion que contiene al menos un agente hidrofilo sensible a la oxidacion por al menos un copolimero de anhidrido maleico. |
US20060058206A1 (en) * | 2002-11-02 | 2006-03-16 | Venture Management Alliance | Aqueous activated components conveyed in a non-aqueous carrier system |
GB0228571D0 (en) * | 2002-12-06 | 2003-01-15 | Novartis Ag | Organic compounds |
AU2004254552B2 (en) | 2003-01-29 | 2008-04-24 | 454 Life Sciences Corporation | Methods of amplifying and sequencing nucleic acids |
WO2004073033A2 (en) | 2003-02-11 | 2004-08-26 | Venture Management Alliance, Llc | Material incapsulation system |
GB0307428D0 (en) * | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
WO2004108792A2 (en) * | 2003-04-10 | 2004-12-16 | Vinod Chintamani Malshe | Novel biodegradable aliphatic polyesters and pharmaceutical compositions and applications thereof |
EP2918595B1 (en) | 2003-07-05 | 2019-12-11 | The Johns-Hopkins University | Method and compositions for detection and enumeration of genetic variations |
DE10357639A1 (de) * | 2003-08-27 | 2005-03-24 | Beiersdorf Ag | Kosmetische und/oder dermatologische Kapsel |
EP1660023B1 (de) * | 2003-08-27 | 2009-01-07 | Beiersdorf AG | Kapsel deren kapselhülle bei topischer anwendung nicht mehr gesondert wahrnehmbar ist |
WO2005020949A1 (de) * | 2003-08-27 | 2005-03-10 | Beiersdorf Ag | Kosmetische kugelförmige zubereitungen zur topischen anwendung |
DE10353780A1 (de) * | 2003-11-18 | 2005-06-23 | Beiersdorf Ag | Partikel aus fester Hülle und potenziell feuchtigkeitsempfindliche oder wasserunlösliche Wirkstoffe enthaltendem flüssigem Kern, Zubereitungen diese enthaltend und Verfahren zu ihrer Herstellung |
WO2005073410A2 (en) * | 2004-01-28 | 2005-08-11 | 454 Corporation | Nucleic acid amplification with continuous flow emulsion |
US20050221339A1 (en) * | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
US20050260275A1 (en) * | 2004-04-01 | 2005-11-24 | Procyte Corporation | Encapsulated peptide copper complexes and compositions and methods related thereto |
BRPI0400438A (pt) * | 2004-04-07 | 2005-11-22 | Botica Com Farmaceutica Ltda | Composição cosmética oleosa com capacidade suspensora |
US20050226900A1 (en) * | 2004-04-13 | 2005-10-13 | Winton Brooks Clint D | Skin and hair treatment composition and process for using same resulting in controllably-releasable fragrance and/or malodour counteractant evolution |
US20050227907A1 (en) * | 2004-04-13 | 2005-10-13 | Kaiping Lee | Stable fragrance microcapsule suspension and process for using same |
US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
US7594594B2 (en) * | 2004-11-17 | 2009-09-29 | International Flavors & Fragrances Inc. | Multi-compartment storage and delivery containers and delivery system for microencapsulated fragrances |
US20070207174A1 (en) * | 2005-05-06 | 2007-09-06 | Pluyter Johan G L | Encapsulated fragrance materials and methods for making same |
GB2426703B (en) * | 2005-05-31 | 2007-09-19 | Malvern Cosmeceutics Ltd | Compositions |
US20070065379A1 (en) * | 2005-09-15 | 2007-03-22 | L'oreal | Microcapsules having an aqueous core and their use in cosmetics |
FR2890558B1 (fr) * | 2005-09-15 | 2007-10-12 | Oreal | Microcapsules a coeur aqueux et leur utilisation en cosmetique |
US8236333B2 (en) * | 2005-10-19 | 2012-08-07 | Unirem, Inc. | Active agent delivery and/or odor retentive composition and methods of use thereof |
EP2363205A3 (en) | 2006-01-11 | 2014-06-04 | Raindance Technologies, Inc. | Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors |
MX2008012247A (es) | 2006-03-30 | 2009-02-20 | Gelesis Inc | Copolimeros de estireno-anhidrido maleico para bioaplicaciones y su preparacion. |
EP2530168B1 (en) | 2006-05-11 | 2015-09-16 | Raindance Technologies, Inc. | Microfluidic Devices |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
WO2008021123A1 (en) | 2006-08-07 | 2008-02-21 | President And Fellows Of Harvard College | Fluorocarbon emulsion stabilizing surfactants |
MX2009005006A (es) * | 2006-11-17 | 2009-05-20 | Ciba Holding Inc | Microcapsulas, su uso y procesos para su fabricacion. |
WO2008097559A2 (en) | 2007-02-06 | 2008-08-14 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
FR2914189A1 (fr) | 2007-03-26 | 2008-10-03 | Oreal | Utilisation d'une fraction lipopolysaccharidique de vitreoscilla filiformis comme agent stimulant la synthese de peptides antimicrobiens de la peau. |
WO2008130623A1 (en) | 2007-04-19 | 2008-10-30 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
FR2918885B1 (fr) | 2007-07-17 | 2009-08-28 | Oreal | Utilisation d'extrait de bacterie cultivee sur eau thermale pour diminuer les poches et/ou les cernes perioculaires |
WO2009071861A2 (fr) * | 2007-11-29 | 2009-06-11 | Lvmh Recherche | Procede de preparation d'une composition cosmetique contenant de la dha, compositions obtenues selon ce procede, et leurs utilisations |
EP4047367A1 (en) | 2008-07-18 | 2022-08-24 | Bio-Rad Laboratories, Inc. | Method for detecting target analytes with droplet libraries |
EP3415235A1 (en) | 2009-03-23 | 2018-12-19 | Raindance Technologies Inc. | Manipulation of microfluidic droplets |
WO2011042564A1 (en) | 2009-10-09 | 2011-04-14 | Universite De Strasbourg | Labelled silica-based nanomaterial with enhanced properties and uses thereof |
EP2517025B1 (en) | 2009-12-23 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Methods for reducing the exchange of molecules between droplets |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
EP2534267B1 (en) | 2010-02-12 | 2018-04-11 | Raindance Technologies, Inc. | Digital analyte analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
DE102010001905A1 (de) * | 2010-02-12 | 2011-08-18 | ROVI Cosmetics International GmbH, 36381 | UV-Schutzmittel für die Haut oder die Haare mit einer in einem vesikulären Trägersystem verkapselten UV-Filtersubstanz |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
BR112012023441A2 (pt) * | 2010-03-17 | 2016-05-24 | Basf Se | emulsificação por fusão |
US9562897B2 (en) | 2010-09-30 | 2017-02-07 | Raindance Technologies, Inc. | Sandwich assays in droplets |
US9364803B2 (en) | 2011-02-11 | 2016-06-14 | Raindance Technologies, Inc. | Methods for forming mixed droplets |
US9150852B2 (en) | 2011-02-18 | 2015-10-06 | Raindance Technologies, Inc. | Compositions and methods for molecular labeling |
DK2681291T3 (da) * | 2011-03-02 | 2016-02-08 | Basf Se | Alkansulfonsyre-mikrokapsler og deres anvendelse ved dybdeboringer |
US8863841B2 (en) | 2011-03-02 | 2014-10-21 | Basf Se | Alkanesulfonic acid microcapsules and use thereof in deep wells |
CN107383898B (zh) | 2011-05-31 | 2020-03-03 | 普立万公司 | 通过热-机械作用具有形状记忆的热塑性弹性体复合物 |
EP3709018A1 (en) | 2011-06-02 | 2020-09-16 | Bio-Rad Laboratories, Inc. | Microfluidic apparatus for identifying components of a chemical reaction |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
WO2013006661A2 (en) * | 2011-07-06 | 2013-01-10 | President And Fellows Of Harvard College | Multiple emulsions and techniques for the formation of multiple emulsions |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
KR102016026B1 (ko) * | 2011-12-07 | 2019-08-29 | 지보당 에스아 | 마이크로캡슐, 마이크로캡슐의 제조 방법 및 마이크로캡슐을 이용하는 조성물 |
US20130157863A1 (en) * | 2011-12-19 | 2013-06-20 | Peter Hahn | Microcapsule dispersion comprising microcapsules with a hydrophilic capsule core |
US9549891B2 (en) | 2012-03-19 | 2017-01-24 | The Procter & Gamble Company | Superabsorbent polymers and sunscreen actives for use in skin care compositions |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
EP3052551B1 (en) | 2013-10-04 | 2021-12-01 | Encapsys, LLC | Benefit agent containing delivery particle |
US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
JP6604637B2 (ja) | 2015-06-29 | 2019-11-13 | ザ プロクター アンド ギャンブル カンパニー | スキンケア組成物において使用するための超吸収性ポリマー及びデンプン粉末 |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
CN109966174B (zh) * | 2017-12-25 | 2022-04-22 | 万华化学集团股份有限公司 | 一种胶囊分散体的制备方法及其应用 |
JP7054954B2 (ja) * | 2018-01-10 | 2022-04-15 | ジー2ジーバイオ インコーポレイテッド | コラーゲンペプチドを含有したポリカプロラクトン微粒球フィラーおよびその製造方法 |
FR3090330B1 (fr) * | 2018-12-20 | 2020-12-04 | Oreal | Composition aqueuse comprenant des capsules à base d’huile gélifiée contenant un actif sensible à l’oxygène |
EP3908246A4 (en) | 2019-01-11 | 2022-11-16 | Encapsys, LLC | INSTALLATION OF CHITOSAN IN A MICROCAPSULE WALL |
CN115960469B (zh) * | 2022-12-13 | 2024-03-15 | 赛轮集团股份有限公司 | 防护蜡缓释微胶囊的制备方法及其应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE634667A (zh) | 1962-07-11 | |||
BE634668A (zh) | 1962-07-11 | |||
DE2010116A1 (de) * | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Verfahren zur Herstellung von Mikrogranulaten |
FR2245335A1 (en) * | 1973-06-28 | 1975-04-25 | Toyo Jozo Kk | Microencapsulated or embedded medicaments prodn - by dispersing org. soln. of medicament and wall matl in carrier |
US4107071A (en) * | 1977-02-16 | 1978-08-15 | Capsulated Systems, Inc. | Method of producing microcapsules and resulting product |
IT1148784B (it) | 1980-04-09 | 1986-12-03 | Eurand Spa | Procedimento per la preparazione di microcapsule in un veicolo liquido |
US4933105A (en) * | 1980-06-13 | 1990-06-12 | Sandoz Pharm. Corp. | Process for preparation of microspheres |
ATE61935T1 (de) * | 1985-02-07 | 1991-04-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von mikrokapseln. |
US5089269A (en) * | 1987-11-07 | 1992-02-18 | Shiseido Company Ltd. | Cosmetic containing fine soft microcapsules |
SE8605515D0 (sv) * | 1986-12-22 | 1986-12-22 | Astra Laekemedel Ab | A liquid dosage form for oral administration of a pharmaceutically active substance |
US4857335A (en) * | 1987-03-27 | 1989-08-15 | Lim Technology Laboratories, Inc. | Liquid controlled release formulations and method of producing same via multiple emulsion process |
JPS6443343A (en) | 1987-08-06 | 1989-02-15 | Pola Chem Ind Inc | Microcapsules and their production |
JP2827287B2 (ja) * | 1988-07-05 | 1998-11-25 | 武田薬品工業株式会社 | 水溶性薬物含有徐放型マイクロカプセル |
US5140043A (en) * | 1989-04-17 | 1992-08-18 | Duke University | Stable ascorbic acid compositions |
DE69024953T3 (de) | 1989-05-04 | 2005-01-27 | Southern Research Institute, Birmingham | Einkapselungsverfahren |
US5232769A (en) | 1989-08-01 | 1993-08-03 | Kanebo, Ltd. | Microcapsule, treating liquids containing the same, and textile structure having microcapsules adhering thereto |
US5238714A (en) * | 1990-10-02 | 1993-08-24 | Board Of Regents, The University Of Texas System | Efficient microcapsule preparation and method of use |
US5154762A (en) * | 1991-05-31 | 1992-10-13 | Minnesota Mining And Manufacturing Company | Universal water-based medical and dental cement |
FR2681248B1 (fr) * | 1991-09-13 | 1995-04-28 | Oreal | Composition pour un traitement cosmetique et/ou pharmaceutique de longue duree des couches superieures de l'epiderme par une application topique sur la peau. |
JPH05285210A (ja) | 1992-04-14 | 1993-11-02 | Terumo Corp | 人工皮膚 |
FR2692812B1 (fr) | 1992-06-24 | 1994-12-30 | Flamel Tech Sa | Microcapsules contenant au moins un principe actif, leurs applications et procédé de préparation de microcapsules renfermant au moins un principe actif. |
FR2698560B1 (fr) | 1992-11-30 | 1995-02-03 | Virbac Laboratoires | Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications. |
FR2703927B1 (fr) | 1993-04-13 | 1995-07-13 | Coletica | Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées. |
US5589194A (en) * | 1993-09-20 | 1996-12-31 | Minnesota Mining And Manufacturing Company | Method of encapsulation and microcapsules produced thereby |
AU2083595A (en) | 1994-04-06 | 1995-10-30 | Takeda Chemical Industries Ltd. | Solid vitamin c preparation and a method of producing the same |
FR2718642B1 (fr) | 1994-04-15 | 1996-07-12 | Pf Medicament | Microsphères biodégradables à libération contrôlée et leur procédé de préparation. |
JPH08325117A (ja) | 1995-06-01 | 1996-12-10 | Kao Corp | 薬効剤含有カプセルの製造法 |
FR2742677B1 (fr) * | 1995-12-21 | 1998-01-16 | Oreal | Nanoparticules enrobees d'une phase lamellaire a base de tensioactif silicone et compositions les contenant |
US5767107A (en) | 1996-09-03 | 1998-06-16 | Basf Corporation | Compositions containing gluten and polysaccharides that contain uronic acid residues useful for encapsulating fats, oils and solids |
DE19802644B4 (de) * | 1998-01-24 | 2010-03-18 | Voco Gmbh | Verfahren zur Herstellung dentaler, wässriger Zementmischungen |
ATE341938T1 (de) * | 1998-02-06 | 2006-11-15 | Zila Nutraceuticals Inc | Stabile flüssige zusammensetzungen von kalzium- ascorbat und verfahren zu ihrer herstellung und verwendung |
DE19810803A1 (de) * | 1998-03-12 | 1999-09-16 | Wacker Chemie Gmbh | Verfahren zur Herstellung mikroverkapselter Produkte mit Organopolysiloxanwänden |
US6348218B1 (en) * | 1999-10-04 | 2002-02-19 | Invent Resources, Inc. | Self dosing skin preparation |
-
2001
- 2001-04-28 CN CNB011156287A patent/CN1189159C/zh not_active Expired - Fee Related
- 2001-04-30 ES ES01401125T patent/ES2269322T3/es not_active Expired - Lifetime
- 2001-04-30 EP EP01401125A patent/EP1151741B1/fr not_active Expired - Lifetime
- 2001-04-30 DE DE60124028T patent/DE60124028T2/de not_active Expired - Lifetime
- 2001-04-30 AT AT01401125T patent/ATE343365T1/de not_active IP Right Cessation
- 2001-05-03 CA CA002346320A patent/CA2346320C/fr not_active Expired - Fee Related
- 2001-05-07 US US09/849,514 patent/US6531160B2/en not_active Expired - Lifetime
- 2001-05-07 JP JP2001135921A patent/JP3933886B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60124028T2 (de) | 2007-03-08 |
DE60124028D1 (de) | 2006-12-07 |
EP1151741A1 (fr) | 2001-11-07 |
CA2346320C (fr) | 2004-07-20 |
US6531160B2 (en) | 2003-03-11 |
CN1323579A (zh) | 2001-11-28 |
US20020022038A1 (en) | 2002-02-21 |
ATE343365T1 (de) | 2006-11-15 |
JP3933886B2 (ja) | 2007-06-20 |
CA2346320A1 (fr) | 2001-11-05 |
EP1151741B1 (fr) | 2006-10-25 |
JP2001354551A (ja) | 2001-12-25 |
ES2269322T3 (es) | 2007-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1189159C (zh) | 含水溶性美容活性组分水性核的微胶囊及含其的组合物 | |
CN1197559C (zh) | 基于水分散阴离子聚合物的毫微囊剂、其制法和化妆组合物 | |
EP0966268B1 (fr) | Particules, en particulier micro- ou nanoparticules de proteines vegetales reticulees, leur procede de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant | |
EP2574337B1 (en) | Carotenoid-containing composition and production method therefor | |
EP1736532A1 (en) | Method for producing calcium component powder containing oil-soluble substance | |
FR2715582A1 (fr) | Microcapsules à paroi de flavonoïde réticulée et compositions en contenant. | |
JP2005500157A (ja) | コーティングされた安定なマイクロカプセル | |
FR2688422A1 (fr) | Microcapsules a parois en polysaccharides contenant des fonctions alcools primaires, et compositions en contenant. | |
JP2004174492A (ja) | ポリオール/高分子マイクロカプセルを用いた酵素及び有効成分の安定化方法、並びにこれを含有する化粧料組成物 | |
CN1357407A (zh) | 共轭亚油酸或共轭亚油酸酯的微胶囊 | |
JP2009185023A (ja) | 粉末組成物及びその製造方法、並びにこれを含む食品組成物、化粧品組成物及び医薬品組成物 | |
JPH03293024A (ja) | レシチンが水相に分散して成る油中水型エマルション | |
JP2004250450A (ja) | 有効成分をマイクロカプセル内に含有する化粧料 | |
JP2003055219A (ja) | マイクロカプセル並びに錠剤、食品用及び医薬品用配合剤 | |
EP4045566B1 (fr) | Polyamides gélifiants biosourcés | |
Okonkwo et al. | Application of biogels for bioactives delivery: Recent developments and future research insights | |
KR100670440B1 (ko) | 아데노신 및 유용성 감초 추출물의 리포좀 기술을 이용한안정화 기술 및 이를 함유하는 화장료 조성물과 그의제조방법 | |
JP5191177B2 (ja) | 粉末組成物及びその製造方法、並びにこれを含む食品組成物、化粧品組成物及び医薬品組成物 | |
JP2008189611A (ja) | 粉末組成物及びその製造方法、並びにこれを含む食品組成物、化粧品組成物及び医薬品組成物 | |
KR100789628B1 (ko) | 레티노이드를 함유하는 경피흡수가 용이한 캡슐, 이것의 제조방법, 이를 함유하는 주름개선용 화장료 조성물 및 이것의 제조방법 | |
EP2752202B1 (en) | Soft capsule pharmaceutical preparation, composition for soft capsule pharmaceutical preparation, and method for producing soft capsule pharmaceutical preparation | |
RU2316390C2 (ru) | Способ получения микрокапсул | |
KR20230009940A (ko) | 비 이소시아네이트 폴리우레탄 엘라스토머 및 이와 같은 엘라스토머를 포함하는 조성물 | |
CN101065107A (zh) | 仅微溶于水或不溶于水的活性物质和单细胞蛋白质材料的混合物的水分散体 | |
WO2004021798A1 (es) | Metodo de preparacion de microcapsulas de astaxantina en quitosano y producto obtenido |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050216 Termination date: 20200428 |